News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Clementia Pharmaceuticals Inc. Announces Closing of $22.5 Million Series A Financing With Preeminent U.S. and Canadian Healthcare Venture Capital Funds
Company licenses exclusive world-wide rights to palovarotene from Roche Pharmaceuticals OrbiMed and BDC Venture Capital investment to advance palovarotene into clinical development for the treatment of FOP MONTREAL, CANADA, January 9, 2014 (Marketwired)  —  Clementia Pharmaceuticals Inc.
View HTML
Toggle Summary Clementia Pharmaceuticals Inc. Announces Key Leadership Appointments
World-class team with extensive orphan drug and rare disease experience to advance palovarotene into clinical development for the treatment of FOP MONTREAL, CANADA, January 29, 2014 (Marketwired)  —  Clementia Pharmaceuticals Inc. , a privately held clinical stage biotechnology company
View HTML
Toggle Summary Clementia Pharmaceuticals Inc. Appoints Francois Nader, M.D. to Board of Directors
Healthcare Industry Veteran Brings Deep Expertise in Developing Innovative Therapies for Patients with Rare Diseases MONTREAL, CANADA, March 26, 2014 (Marketwired)  —  Clementia Pharmaceuticals Inc. , a privately held clinical-stage biotechnology company dedicated to serving those
View HTML
Toggle Summary Clementia Pharmaceuticals Marks Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day
MONTREAL, CANADA, April 23, 2014  —  Clementia Pharmaceuticals Inc. , a privately held clinical stage biotechnology company dedicated to serving those afflicted with severe and rare diseases through the development and commercialization of innovative treatments, observes the 2014
View HTML
Toggle Summary Clementia Pharmaceuticals Initiates Phase 2 Study of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva (FOP)
MONTREAL, CANADA and BOSTON, MA, July 14, 2014 (Marketwired)  —  Clementia Pharmaceuticals Inc.  announced today the initiation of a Phase 2 clinical trial of palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP).
View HTML
Toggle Summary Clementia Pharmaceuticals Receives U.S. Orphan Drug Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva
MONTREAL, CANADA and BOSTON, MA, July 24, 2014  (Marketwired) —  Clementia Pharmaceuticals Inc. , announced today that the U.S. Food and Drug Administration (FDA) has granted the Company’s lead product candidate, palovarotene, Orphan Drug Designation for the treatment of Fibrodysplasia
View HTML
Toggle Summary Clementia Pharmaceuticals Announces Open-Label Phase 2 Extension Study of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
MONTREAL, CANADA, OCTOBER 27, 2014  –  Clementia Pharmaceuticals Inc.  announced today the initiation of a Phase 2 extension study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful,
View HTML
Toggle Summary Phase 2 Clinical Trial Milestone
Clementia Completes Enrollment Of First Cohort In Phase 2 Clinical Trial! February 5, 2015: Clementia is pleased to announce the enrollment of the 8th patient in Cohort 1 of its Phase 2 clinical trial of palovarotene for the treatment of FOP! This important milestone triggers the Data Monitoring
View HTML
Toggle Summary Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva
MONTREAL, CANADA, NOVEMBER 21, 2014  –  Clementia Pharmaceuticals Inc.  announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company’s lead product candidate, for the treatment of fibrodysplasia ossificans
View HTML
Toggle Summary Clementia Pharmaceuticals Receives Fast Track Designation for Palovarotene for Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
MONTREAL, CANADA, December 1, 2014  –  Clementia Pharmaceuticals Inc.  announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
View HTML